Currently, selective CDK7 inhibitors such as Q901, TY-2699a, XL-102, and SY-5609, are being explored as monotherapies or in combination with other drugs for treating advanced solid tumors, including breast cancer (Table 3). This evidence concerns the gene CDK7 and breast carcinoma.